Keros Therapeutics, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing, not a standalone fourth-quarter report; the supplied text does not provide clear Q4-only financial results.
Business context
Keros is a clinical-stage biopharmaceutical company developing therapeutics targeting TGF-β signaling. Its lead candidate, KER-050, is being studied for cytopenias in myelodysplastic syndromes (MDS) and myelofibrosis; KER-012 is in development for pulmonary arterial hypertension (PAH) and cardiovascular disorders; and KER-065 is being developed for obesity and neuromuscular diseases. No candidates are approved, and the company has not generated product-sales revenue.
Financial results and liquidity
| Metric | FY2023 | FY2022 | Change / context |
|---|---|---|---|
| Revenue | $0.2 million | $0 | FY2023 revenue was technology-transfer services for Hansoh; FY2021 included a $20.0 million license fee. |
| Research and development expense | $135.3 million | $87.3 million | Increased $48.0 million, led by KER-050, KER-012, manufacturing, personnel and facility costs. |
| General and administrative expense | $34.8 million | $27.5 million | Increased $7.3 million, including higher personnel and stock-based compensation. |
| Loss from operations | $169.9 million | $114.8 million | Operating loss widened as development spending grew. |
| Other income, net | $16.9 million | $10.1 million | Included $14.8 million of dividend income and $2.4 million of Australian R&D incentive income. |
| Net loss | $153.0 million | $104.7 million | Loss increased $48.3 million; loss per share was $5.20 versus $4.15. |
| Net cash used in operating activities | $124.5 million | $70.1 million | Cash burn increased substantially. |
| Cash and cash equivalents | $331.1 million | $279.0 million | Year-end balance; restricted cash was an additional $1.2 million. |
Revenue was immaterial relative to operating expenses, so a revenue-based operating margin is not informative. The company reported no debt subject to variable interest rates; balance-sheet liabilities were $37.8 million, primarily operating lease liabilities. Operating lease commitments totaled $21.4 million. FY2023 financing cash flow of $179.0 million was mainly from ATM share sales. A January 2024 public offering generated approximately $151.0 million net proceeds; management says cash plus those proceeds is expected to fund operating and capital requirements into 2027, subject to assumptions.
Material changes and operating developments
- R&D spending rose 55% to $135.3 million. KER-050 expense increased $16.8 million and KER-012 expense increased $8.5 million; personnel expense also rose $15.7 million.
- Operating cash use rose from $70.1 million to $124.5 million, while net loss increased from $104.7 million to $153.0 million.
- The company sold 4.06 million shares through its ATM program in 2023 for approximately $175.8 million net proceeds, adding to potential shareholder dilution.
- In November 2023, Keros deprioritized KER-047 and paused its development activities.
- Keros exited emerging growth company status on December 31, 2023. Management and the auditor reported effective internal control over financial reporting; the auditor issued unqualified opinions on the financial statements and controls.
Pipeline, outlook and risks
- KER-050 in MDS: In an ongoing open-label Phase 2 study, 30 of 60 evaluable patients had an overall erythroid response in the first 24 weeks. Among transfusion-independence-evaluable patients, 18 of 46 achieved at least eight weeks of transfusion independence. These interim findings are not from a controlled pivotal trial. Keros expected additional data in Q2 and Q4 2024 and planned regulatory discussions on Phase 3 design in H1 2024.
- KER-050 in myelofibrosis: Interim Phase 2 findings included hemoglobin increases in non-transfusion-dependent patients, reduced transfusion burden in many patients, spleen-size reduction in 4 of 7 assessed patients with enlarged spleens, and symptom-score decreases in 8 of 12 assessed patients meeting the stated baseline criteria. Additional data were expected in Q2 and Q4 2024.
- KER-012: The PAH Phase 2 TROPOS trial was ongoing; an enrollment update was expected in H1 2024. Initial data from an exploratory heart-failure biomarker trial were expected in H2 2024.
- KER-065: A Phase 1 trial in healthy volunteers had begun; initial data were expected in Q1 2025, followed by a planned proof-of-concept study in obese patients.
- Funding and execution: Keros expects ongoing losses and negative operating cash flows and will need substantial capital for development. Its stated runway into 2027 depends on estimates and may be shorter; further equity financing could dilute shareholders. Clinical outcomes, recruitment, regulatory decisions and manufacturing remain uncertain.
- Other risks: All candidates are investigational; early or open-label data may not predict pivotal results. Keros relies on third-party manufacturers, has no redundant supply arrangements, and identifies single-source supply risks. Competition includes approved and developing therapies, including Reblozyl and Ojjaara in relevant hematology settings, and sotatercept development in PAH. Coverage, pricing, intellectual-property and clinical-trial risks also apply.
Important facts for investors to verify
- Review full audited statements and notes, particularly the composition and liquidity of cash, the $124.5 million operating cash burn, and the assumptions supporting runway into 2027.
- Track final, controlled KER-050 trial results and the regulatory-agreed Phase 3 design; assess how interim response rates compare with prespecified endpoints and relevant alternatives.
- Check subsequent KER-012 and KER-065 trial enrollment, safety and efficacy disclosures against the stated timelines.
- Quantify dilution from the 2023 ATM issuance, January 2024 offering, remaining ATM capacity and equity-compensation plans.
- Monitor reliance on single-source contract manufacturers, lease obligations, and whether Hansoh achieves development or commercial milestones; no Hansoh milestones had been achieved by December 31, 2023.